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OBJECTIVE — Type 2 diabetes is associated with a moderate degree of cerebral atrophy and
a higher white matter hyperintensity (WMH) volume. How these brain-imaging abnormalities
evolve over time is unknown. The present study aims to quantify cerebral atrophy and WMH
progression over 4 years in type 2 diabetes.
RESEARCH DESIGN AND METHODS — A total of 55 patients with type 2 diabetes
and 28 age-, sex-, and IQ-matched control participants had two 1.5T magnetic resonance imaging
scans with a 4-year interval. Volumetric measurements of total brain, peripheral cerebrospinal ﬂuid
(CSF), lateral ventricles, and WMH were performed with k-nearest neighbor–based probabilistic
segmentation. All volumes were expressed as percentage of intracranial volume. Linear regression
analyses,adjustedforageandsex,wereperformedtocomparebrainvolumesbetweenthegroupsand
to identify determinants of volumetric change within the type 2 diabetic group.
RESULTS — At baseline, patients with type 2 diabetes had a signiﬁcantly smaller total brain
volume and larger peripheral CSF volume than control participants. In both groups, all volumes
showed a signiﬁcant change over time. Patients with type 2 diabetes had a greater increase in
lateralventricularvolumethancontrolparticipants(meanadjustedbetween-groupdifferencein
change over time [95% CI]: 0.11% in 4 years [0.00 to 0.22], P  0.047).
CONCLUSIONS — The greater increase in lateral ventricular volume over time in patients
with type 2 diabetes compared with control participants shows that type 2 diabetes is associated
with a slow increase of cerebral atrophy over the course of years.
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N
umerous studies have shown an as-
sociation between type 2 diabetes
and mild to moderate cognitive im-
pairment and an increased risk of demen-
tia (1,2). However, the underlying
mechanisms are still unclear. Structural
correlates of diabetes-related cognitive
impairment can be assessed with brain
magnetic resonance imaging (MRI) (3).
Cross-sectionalstudiesusingeithervisual
rating scales or automated volumetric
techniquesonmagneticresonanceimages
showed that type 2 diabetes is associated
with a moderate degree of cerebral atro-
phy (rev. in 4). The association of type 2
diabetes and white matter hyperintensi-
ties (WMH) is less robust, since some
studies found an association to more ex-
tensive WMH (5), whereas other studies
did not (6). The progression of cerebral
atrophy and WMH volume over time in
patients with type 2 diabetes is still un-
clear.Consequently,riskfactorsrelatedto
progressionofbrainabnormalitiesintype
2 diabetes are largely unknown.
The present study aimed to quantita-
tively determine the effect of type 2 dia-
betes on cerebral atrophy and WMH
progression over 4 years. Within the
group with type 2 diabetes, the relation-
ship between changes in brain volumes
and metabolic and vascular risk factors
was also assessed.
RESEARCH DESIGN AND
METHODS— At baseline (2002–
2004)122participantswithtype2diabe-
tes and 56 age-, sex-, and IQ-matched
control participants were included; all
were between 56 and 80 years of age
(7,8). Patients with type 2 diabetes were
recruited through their general practitio-
ners. Control participants were recruited
among the spouses and acquaintances of
the patients. All participants were func-
tionally independent and Dutch speak-
ing. Patients had to have a diabetes
duration of at least 1 year. Exclusion cri-
teria were a psychiatric or neurological
disorder (unrelated to diabetes) that
could inﬂuence cognitive functioning, a
historyofalcoholorsubstanceabuse,ora
history of dementia. Control participants
with a fasting glucose 7.0 were also
excluded.
All participants were invited for fol-
low-up 4 years later (2006–2008). Base-
line scans that could be used for
volumetric analyses were available in 110
participants with type 2 diabetes and in
50 control participants. Of these 160 par-
ticipants, 6 had died, 4 could not be con-
tacted, 2 were excluded based on the
exclusion criteria (1 control participant
had a fasting glucose 7.0 and 1 patient
had severe comorbid disease), and 63
were not able or willing to participate in
the follow-up. Reasons for not participat-
ing were lack of interest (n  26); comor-
bidity (n  20; three reported dementia:
twopatientsandonecontrolparticipant);
unwillingness or new contraindications
to undergo MRI, such as a pacemaker
(n  9); or other reasons (n  8). Two
participants were excluded based on arti-
facts in the scans, which made reliable
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This left a total of 83 participants (55 pa-
tients and 28 control participants, mean
follow-up time: 4.1  0.4 years) for in-
clusion in the present study.
Age and sex distribution and esti-
mated IQ at baseline were not signiﬁ-
cantly different between participants
included (n  83) and not included (n 
77) in this follow-up MRI study. Impor-
tantly, baseline brain volumes (7) were
also not signiﬁcantly different between
participants and nonparticipants. The
study was approved by the medical ethics
committeeoftheUniversityMedicalCen-
ter Utrecht, and all participants signed an
informed consent form.
Medical history and physical
examination
At baseline and follow-up, the same stan-
dardized interview was used to question
participants about level of education
(seven categories), medication use, hy-
percholesterolemia, smoking, history of a
macrovascular event (myocardial infarc-
tion or stroke requiring hospitalization or
surgicalorendovasculartreatmentofath-
erosclerotic arterial disease), and diabetes
duration. At baseline and follow-up,
weight and height were measured and
blood samples were taken to determine
A1C, fasting glucose, and cholesterol lev-
els. At baseline, blood pressure was mea-
sured automatically at home on 10
different time points during the day. At
follow-up, blood pressure was measured
in a seated position at three time points
during the half-day visit. Mean arterial
pressures were calculated from these
measurements. Hypertension was de-
ﬁned as a systolic blood pressure 160
mmHg or diastolic blood pressure 95
mmHg or self-reported use of blood pres-
sure–loweringdrugsprescribedprimarily
for hypertension. Hypercholesterolemia
was deﬁned as a fasting cholesterol 6.2
mmol/l or self-reported use of lipid-
lowering drugs. BMI was calculated as
weight (in kilograms) divided by the
square of height (in meters). All partici-
pants had a neurological examination at
baseline and follow-up; none of the par-
ticipants had focal abnormalities sugges-
tive of central lesions, such as infarcts.
IQ was estimated with the Dutch ver-
sion of the National Adult Reading Test,
which is generally accepted to reﬂect the
premorbid level of intellectual function-
ing (8,9). To control for selective loss to
follow-up, the cognitive status of partici-
pants (a week after participation in the
follow-up examination) and nonpartici-
pants was assessed with the modiﬁed
DutchversionoftheTelephoneInterview
for Cognitive Status (TICS-m), a screen-
ing instrument designed to identify peo-
ple with dementia (10,11). A cutoff score
of28isindicativeofcognitiveimpairment
(12).
MRI scanning protocol
MRI scans were acquired at baseline and
follow-up on a 1.5T Philips magnetic res-
onance system using a standardized pro-
tocol (38 contiguous slices, voxelsize:
0.9  0.9  4.0 mm) and consisted of an
axial T1 (repetition time in ms [TR]: 234,
echo time in ms [TE]: 2), T2 (TR: 2,200,
TE:100),protondensity(PD)(TR:2,200,
TE: 11), inversion recovery (IR) (TR:
2,919, TE: 22, inversion time in ms [TI]:
410), and ﬂuid-attenuated inversion re-
covery (FLAIR) (TR: 6,000, TE: 100, TI:
2,000).
Image processing
On both time points, all images (T1, T2,
PD, and IR) of each participant were rig-
idly registered to the FLAIR image by us-
ing Elastix (13). Scan inhomogeneities
were corrected by a shading correction
algorithm (14).
To exclude all nonbrain and non–
cerebrospinal ﬂuid (CSF) tissue, a brain
maskwascreatedforeveryparticipantus-
ing all baseline images in a k-means–
clustering algorithm with eight clusters
(7). The clusters that contained brain and
CSF were combined, and additional non-
brain and non-CSF structures in the
formed mask were automatically ex-
cluded and holes were ﬁlled by using a
standardized protocol of morphological
operators. A 3-voxel dilation of the mask
wasperformedtoincludeallCSF,andthe
result was manually adjusted to only con-
tain tissue above the foramen magnum.
To construct a follow-up mask with
the same brain coverage, the baseline
FLAIR was rigidly registered to the fol-
low-up FLAIR of the same participant,
and the resulting transform parameters
were used to transform the baseline brain
mask (13). A standardized combination
of morphological operators was applied
to ﬁll holes and smooth the follow-up
mask. The uncorrected FLAIR images
were multiplied voxelwise by the binary
brainmask,followedbyashadingcorrec-
tion to provide better correction (14).
Forthevolumemeasurementsonone
timepoint,thebrainmask,FLAIR,andIR
were used. Volumes were measured by
k-nearest neighbor–based probabilistic
segmentation,anautomaticandvalidated
approach to brain segmentation (15).
This method is based on manually classi-
ﬁed training data, which consists of
FLAIR and IR images of 10 matched sub-
jects with a different extent of cerebral at-
rophy and WMH made by an identical
scanning protocol to the images in this
study. Gray and white matter, peripheral
CSF (CSF without lateral ventricles), lat-
eral ventricular, and WMH volume were
automatically classiﬁed.
The results of the probabilistic classi-
ﬁcation of all tissues were visually
checked for all participants, and incor-
rectly classiﬁed images were excluded. In
twoparticipants,asmallmeningiomawas
found, which was manually excluded. To
reducetheeffectsofnoise,theWMHclas-
siﬁcation was thresholded on a 0.5 prob-
ability, after which isolated classiﬁed
voxels were automatically excluded. The
automated segmentation tends to classify
the gliotic core around infarcts as WMH.
Because this confounds the measurement
of WMH volume, infarcts were manually
segmented from the WMH volume and
added to the total brain volume. The total
volume of the individual tissues was cal-
culated by multiplying the probabilities
by the voxel volume. To correct for be-
tween-subject differences in intracranial
volume (volume of all classiﬁed tissues
combined), all baseline and follow-up
volumes were expressed as a percentage
of intracranial volume. Total brain vol-
ume (gray and white matter  WMH 
infarcts) was calculated on both time
points. The total brain, peripheral CSF,
lateral ventricular, and WMH volume
were analyzed.
Statistical analysis
Participantcharacteristicswerecompared
between the type 2 diabetic group and
the control group using independent-
samples t tests. TICS-m scores were
compared between participants and non-
participants at the follow-up examination
by an independent-samples t test and dif-
ferences in loss to follow-up between
groups were assessed by Pearson 
2 tests.
Within-group changes in brain volumes
over time were assessed by using paired t
tests. Because of nonnormal distribution
(Kolmogorov-Smirnov, P  0.05), pro-
gression of WMH volume was analyzed
byaWilcoxonsigned-ranktest.Linearre-
gression analyses adjusted for age and sex
were performed to assess the relationship
between baseline brain volumes and
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umechangeovertimeandgroup.Baseline
WMH volume was multiplied by 100 and
naturally log transformed because of non-
normal distribution. Additionally, separate
analyses were done for men and women,
because differences in cerebral tissue vol-
umeswerefoundatthebaselineexamina-
tion (7).
To identify possible determinants of
baseline brain volume and volume
change over time, linear regression anal-
yses adjusted for age and sex were per-
formed within the type 2 diabetic group.
Determinants that were considered in-
cluded diabetes duration, A1C levels,
mean arterial pressure, hypertension, to-
tal cholesterol levels, hypercholesterol-
emia,BMI,andhistoryofamacrovascular
event.
RESULTS— Table 1 shows the base-
line characteristics of the patients with
type 2 diabetes and the control partici-
pants. The groups are similar with regard
to age, sex distribution, and estimated IQ
(P  0.05). As expected, the groups dif-
fered on vascular risk factors and glyce-
mic control. At follow-up, nine patients
and three control participants had new
brain infarcts. Levels of risk factors re-
mained unchanged over time.
A TICS-m was obtained from 51
(76% with diabetes) of 67 nonpartici-
pantsatfollow-upwhowerestillaliveand
could be contacted and from 79 (66%
with diabetes) of 83 participants. The
TICS-m score was similar and normally
distributed for participants and nonpar-
ticipants (participants mean 36.9  4.4,
nonparticipants 35.1  6.0, P  0.05).
Among all nonparticipants, three patients
with type 2 diabetes (3% of baseline sam-
ple) and two control participants (4% of
baseline) had marked cognitive impair-
ment based on caregiver-reported de-
mentia or a TICS-m score 28 [
2 (1) 
0.34,P0.56](10).Table2showsbase-
line volumes and differences between
baseline and follow-up volumes. In both
groups,totalbrainvolumedecreasedover
time and peripheral CSF, lateral ventric-
ular, and WMH volume increased over
time (all P  0.001 in both groups).
At baseline, patients with type 2 dia-
betes had a signiﬁcantly smaller total
brain volume (adjusted difference be-
tween type 2 diabetes and control group
[95% CI] 1.36% [2.31 to 0.40],
P0.006)andlargerperipheralCSFvol-
ume (0.98% [0.07 to 1.90], P  0.036).
The lateral ventricular volume showed a
greaterincreaseovertimeinpatientswith
type 2 diabetes than in control partici-
pants (adjusted difference in change over
time between type 2 diabetes and control
group [95% CI] 0.11% in 4 years [0.00 to
0.22],P0.047).Relativetothebaseline
ventricular volume, this reﬂects a 3.6%
larger increase in the diabetic than in the
Table 1—Baseline participant characteristics
Control
participants
Patients with
type 2 diabetes P values
Demographics
Men/women 12/16 26/29 0.71
Age (years) 64.2  4.3 65.9  5.4 0.16
Level of education* 4.5  1.3 4.2  1.5 0.47
Estimated IQ 98  15 97  14 0.66
Time to follow-up (years) 4.1  0.4 4.1  0.4 0.58
Risk factors for heart and vessel disease
Mean arterial pressure (mmHg) 107  13 113  14 0.07
Use of antihypertensive drugs (%) 29 66 0.001
Hypercholesterolemia (%)† 46 60 0.25
Smoking ever (%) 50 67 0.13
BMI (kg/m
2) 27 28 0.20
Any macrovascular event (%)‡ 7 31 0.004
Brain infarcts on MRI (%) 21 25 0.69
Diabetes-related factors
Diabetes duration (years) — 9.5  6.6 —
A1C level (%) 5.5  0.3 7.0  1.1 0.001
Fasting glucose (mmol/l) 5.6  0.6 8.8  2.8 0.001
Use of insulin (%) — 31 —
DataaremeansSDorpercentagesoftotalgroup.*Sevencategories.†Deﬁnedasafastingcholesterol6.2
mmol/l or self-reported use of lipid-lowering drugs. ‡Deﬁned as a myocardial infarction or stroke requiring
hospitalization or surgical or endovascular treatment of atherosclerotic arterial disease.
Table 2—Mean volumes and changes in volumes over time in patients with type 2 diabetes and control participants
Total brain Peripheral CSF Lateral ventricles WMH*
Control participants
Volume at baseline (%) 79.9  2.0 18.1  1.6 2.01  1.18 0.28  0.42
Change over time (%) 1.21  0.66† 0.96  0.62† 0.23  0.21† 0.12  0.28‡
Patients with type 2 diabetes
Volume at baseline (%) 78.1  2.6 19.4  2.4 2.49  1.05 0.39  0.78
Change over time (%) 1.46  0.71† 1.10  0.64† 0.36  0.25† 0.14  0.18†
Differences between patients and
control participants
Difference in baseline volume 1.36 (2.31 to 0.40)‡ 0.98 (0.07 to 1.90)§ 0.37 (0.12 to 0.87) 0.35 (0.13 to 0.83)
Difference in change over time 0.18 (0.49 to 0.13) 0.09 (0.20 to 0.38) 0.11 (0.00 to 0.22)§ 0.02 (0.09 to 0.12)
DataareunadjustedmeanrelativebrainvolumesSDandchangesinbrainvolumeovertimeSD(meandifferencebetweenrelativebaselineandrelativefollow-up
volume) or adjusted (age and sex) between-group differences (regression B coefﬁcients (95% CI)) in relative baseline volumes and relative change in brain volumes
over time. *For the differences in WMH volume between patients and control participants, baseline WMH volumes were multiplied by 100 and naturally log
transformed. †P  0.001; ‡P  0.01; within-group change, paired t test or Wilcoxon signed-rank test. ‡P  0.01; §P  0.05; between-group differences, linear
regression analyses.
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tricular volume: patients: 15.2  12.9%,
control participants: 11.6  7.8%). Total
brain, peripheral CSF, and WMH volume
showednosigniﬁcantbetween-groupdif-
ferences in change over time (P  0.05).
At follow-up, 14 control participants had
impaired fasting glucose levels (5.6–6.9
mmol/l). Brain volumes at baseline and
changesinvolumeovertimeinthisgroup
were similar to the other control partici-
pants. Moreover, if these 14 individuals
were removed from the comparison be-
tween the diabetic and control group, the
results remained essentially the same.
In separate analyses for individuals
below and above the age of 65 years, the
differences between the diabetic and con-
trol group remained largely identical
(data not shown). In separate analyses for
men and women, female patients with
type 2 diabetes compared with female
control participants had a smaller base-
line total brain volume (2.07% [3.36
to 0.78], P  0.002), a larger baseline
peripheral CSF (1.28% [0.09 to 2.47],
P0.036)andlateralventricular(0.78%
[0.25 to 1.32], P  0.005) volume, and a
greater increase in lateral ventricular vol-
ume over time (0.21% in 4 years [0.04 to
0.37], P  0.016). Although the direc-
tions of these effects were similar in male
participants, no signiﬁcant baseline or
longitudinal between-group differences
were found for male participants (P 
0.05).
In Table 3, the secondary analyses on
metabolicandvascularriskfactorswithin
the type 2 diabetic group are shown ad-
justed for age and sex. Increasing age was
associated with a smaller total brain vol-
ume (volume difference per 5-year in-
creaseofage[95%CI]1.00%[1.59to
0.41], P  0.001) and a larger periph-
eral CSF volume (0.93% [0.38 to 1.48],
P  0.001). Increasing age was also asso-
ciated with a greater decrease in total
brain volume over time (difference in
change over time per 5-year increase of
age 0.06% per year [0.10 to 0.02],
P  0.005) and a greater increase in pe-
ripheral CSF volume (0.05% per year
[0.01 to 0.09], P  0.010). The presence
of hypertension at baseline was not asso-
ciated with baseline brain volumes, but
hypertension was associated with a
greater decrease in total brain volume
over time (difference in change over time
between patients with hypertension ver-
sus no hypertension 0.10% per year
[0.20 to 0.01], P  0.033) and a
greaterincreaseinperipheralCSFvolume
(0.12% per year [0.04 to 0.20], P 
0.006). No signiﬁcant associations be-
tween baseline brain volumes or brain
volume change and sex, diabetes dura-
tion, A1C level, mean arterial pressure,
total cholesterol levels, hypercholesterol-
emia,BMI,andhistoryofamacrovascular
event were found (P  0.05).
CONCLUSIONS — At baseline pa-
tients with type 2 diabetes had more ce-
rebral atrophy than control participants.
Both the control and the type 2 diabetic
groupshowedasigniﬁcantprogressionof
cerebral atrophy and WMH volume over
4 years. Patients with type 2 diabetes had
Table 3—Relationship between baseline determinants and baseline volumes and volume change over time in patients with type 2 diabetes
Total brain Peripheral CSF Lateral ventricles WMH*
Baseline
Age (per 5 years) 1.00 (1.59 to 0.41)† 0.93 (0.38 to 1.48)† 0.07 (0.20 to 0.35) 0.17 (0.08 to 0.43)
Male sex 1.16 (2.43 to 0.10) 1.01 (0.17 to 2.19) 0.16 (0.42 to 0.74) 0.23 (0.77 to 0.32)
Diabetes duration (per 5 years) 0.03 (0.49 to 0.55) 0.03 (0.46 to 0.52) 0.06 (0.30 to 0.18) 0.16 (0.37 to 0.06)
A1C level (%) 0.00 (0.58 to 0.57) 0.05 (0.58 to 0.49) 0.05 (0.22 to 0.31) 0.02 (0.26 to 0.23)
Mean arterial pressure
(per 10 mmHg) 0.02 (0.45 to 0.48) 0.01 (0.45 to 0.42) 0.01 (0.22 to 0.21) 0.11 (0.09 to 0.31)
Hypertension‡ 0.49 (1.89 to 0.92) 0.28 (1.04 to 1.60) 0.20 (0.45 to 0.85) 0.22 (0.82 to 0.39)
Total cholesterol (mmol/l) 0.28 (1.00 to 0.44) 0.06 (0.62 to 0.73) 0.23 (0.10 to 0.55) 0.00 (0.31 to 0.31)
Hypercholesterolemia§ 0.22 (1.20 to 1.64) 0.08 (1.25 to 1.42) 0.31 (0.96 to 0.34) 0.04 (0.65 to 0.57)
BMI (kg/m
2) 0.05 (0.21 to 0.12) 0.10 (0.05 to 0.25) 0.05 (0.13 to 0.02) 0.03 (0.10 to 0.04)
Macrovascular event  1.11 (2.49 to 0.26) 0.86 (0.44 to 2.16) 0.24 (0.41 to 0.88) 0.15 (0.75 to 0.46)
Longitudinal change over 4 years
Age (per 5 years) 0.25 (0.42 to 0.08)† 0.21 (0.05 to 0.36)¶ 0.04 (0.02 to 0.10) 0.01 (0.03 to 0.06)
Male sex 0.06 (0.42 to 0.31) 0.12 (0.21 to 0.45) 0.06 (0.20 to 0.07) 0.06 (0.16 to 0.04)
Diabetes duration (per 5 years) 0.07 (0.08 to 0.22) 0.05 (0.19 to 0.08) 0.01 (0.07 to 0.04) 0.01 (0.05 to 0.03)
A1C level (%) 0.02 (0.15 to 0.18) 0.05 (0.20 to 0.10) 0.03 (0.03 to 0.10) 0.03 (0.01 to 0.08)
Mean arterial pressure
(per 10 mmHg) 0.08 (0.21 to 0.06) 0.06 (0.06 to 0.18) 0.02 (0.04 to 0.07) 0.01 (0.04 to 0.03)
Hypertension‡ 0.43 (0.81 to 0.04)¶ 0.49 (0.15 to 0.83)† 0.06 (0.22 to 0.09) 0.06 (0.17 to 0.05)
Total cholesterol (mmol/l) 0.04 (0.25 to 0.16) 0.01 (0.20 to 0.18) 0.05 (0.03 to 0.13) 0.00 (0.06 to 0.06)
Hypercholesterolemia§ 0.01 (0.40 to 0.42) 0.03 (0.35 to 0.40) 0.03 (0.19 to 0.12) 0.02 (0.13 to 0.09)
BMI (kg/m
2) 0.01 (0.06 to 0.04) 0.02 (0.02 to 0.06) 0.01 (0.03 to 0.01) 0.00 (0.02 to 0.01)
Macrovascular event  0.12 (0.52 to 0.29) 0.12 (0.25 to 0.49) 0.00 (0.15 to 0.15) 0.04 (0.07 to 0.15)
DataareregressionBcoefﬁcients(95%CI)foreachdeterminant,adjustedforageandsex.Baselinevolumesandchangeinvolumesovertimearedescribedseparately.
Relative total brain volume decreases and relative peripheral CSF, lateral ventricular, and WMH volume increases over time. Therefore, negative B values in change
over time reﬂect a greater decrease in relative total brain volume, whereas in the other volumes positive B values reﬂect a greater increase of these volumes. *Relative
baseline WMH volumes were multiplied by 100 and naturally log transformed. †P  0.01. ‡Deﬁned as a systolic blood pressure 160 mmHg or diastolic blood
pressure 95 mmHg or self-reported use of blood pressure–lowering drugs prescribed primarily for hypertension. §Deﬁned as a fasting cholesterol 6.2 mmol/l
or self-reported use of lipid-lowering drugs.  Deﬁned as a myocardial infarction or stroke requiring hospitalization or surgical or endovascular treatment of
atherosclerotic arterial disease. ¶P  0.05.
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volume than control participants. In ex-
plorative analyses on risk factors within
the type 2 diabetic group, increasing age
was associated with more cerebral atro-
phy and increasing age and the presence
of hypertension at baseline were associ-
ated with greater progression of cerebral
atrophy.
The baseline ﬁndings of our study are
inlinewithpreviouscross-sectionalstud-
ies, which consistently report an associa-
tion between type 2 diabetes and modest
cerebral atrophy (rev. in 3). To the best of
our knowledge, no longitudinal studies
that speciﬁcally addressed progression of
cerebral atrophy over time in type 2 dia-
betes have been published. However, in a
longitudinal study on cardiovascular risk
factors and dementia in the elderly, dia-
betes was found to be associated with a
greater increase in lateral ventricular vol-
ume (16). Moreover, some cross-
sectional studies observed an association
between diabetes duration and severity of
cerebralatrophy(6,17)butnotinvariably
(7). In combination with the results of
thesepreviousstudies,ourresultssuggest
thatcerebralatrophyinpatientswithtype
2 diabetes progresses only slowly relative
to control participants over the course of
years. Hence, the average rate of decline
in patients with type 2 diabetes stayed
within the range of normal ageing and
does not approach the accelerated loss
that is observed in disease states such as
Alzheimer’s disease (18). It is important
to note that in our study population, cog-
nitive decline was also not accelerated in
the type 2 diabetic group relative to con-
trol participants (10).
Cross-sectional studies on the associ-
ation between type 2 diabetes and WMH,
as assessed with visual rating scales,
showed inconsistent results (rev. in 4).
However, when detailed rating scales
were used, a modest association with
deep WMH was observed (5,8). Recent
longitudinal studies (19,20) on the asso-
ciation between WMH progression and
vascular risk factors in the elderly re-
ported an association between diabetes
and an increased WMH progression rate.
We found no signiﬁcant association be-
tween type 2 diabetes and WMH volume
for cross-sectional as well as longitudinal
measurements in the present study,
whereas we did observe an association in
our baseline cohort (7). This discrepancy
can be explained by the relatively large
interindividual variability in WMH vol-
ume, the small difference in WMH vol-
ume between groups combined with the
relatively limited sample size of the
present study. Volumetric methods that
can also make a distinction in periven-
tricular and deep WMH and a larger sam-
ple size are needed to look at this
association in more detail.
The sex-related differences in base-
line brain volumes between groups ob-
served in our study were comparable to
the differences found in our baseline
study in which between-group brain vol-
umedifferenceswerealsoonlysigniﬁcant
forfemaleparticipants(7).Previousstud-
ies on cognitive functioning or dementia
in patients with diabetes did not observe
sex-speciﬁc increases in the rate of cogni-
tive decrements (2). However, it must be
noted that the effect of sex on brain vol-
umechangeandcognitionindiabeteshas
not yet been analyzed systematically, and
this is a topic that will need to be ad-
dressed in further studies.
Relatively few studies have speciﬁ-
cally examined metabolic and vascular
determinantsofbrain-imagingabnormal-
ities in patients with type 2 diabetes.
Cross-sectional studies (7,17,21,22) re-
porthypertension,diabetesduration,and
history of macrovascular events as deter-
minants of cerebral atrophy and diabetes
duration as a determinant of WMH vol-
ume. In the present study, hypertension
was a determinant of cerebral atrophy
progression. Cross-sectional studies in
community-dwelling elderly subjects
showed A1C level as a determinant of
WMHvolumeandA1CandBMIasdeter-
minants of cerebral atrophy (23,24). Fur-
thermore, in longitudinal population-
based studies, not speciﬁcally in
individuals with diabetes, a history of
stroke was found as a determinant of
WMH progression, and A1C levels, and
BMI and severe WMH were found as de-
terminants of cerebral atrophy progres-
sion (19,24). Studies on cognitive
dysfunction in type 2 diabetes have iden-
tiﬁed both vascular factors and elevated
A1C as possible determinants (8,25), but
results are not always consistent across
studies. Importantly, no causality can be
inferredfromsuchassociations.Although
experimental studies identify several pos-
sible mechanisms that may contribute to
cerebral damage in type 2 diabetes, in-
cluding glucose toxicity, vascular distur-
bances,andabnormalinsulinsignalingin
the brain, it is yet unclear which of these
factors are the main causal factors of cere-
bral damage in humans (2).
The strength of the present study is
the prospective design in combination
with precise automatic brain volume
measurements and detailed assessment of
metabolic and vascular determinants in
patients and control participants. The ob-
served changes in brain volumes over
timearewelloutsidetheerrorofmeasure-
ment of our method. Limitations include
the loss to follow-up, which can lead to
possible selection bias. Nevertheless,
compared with the participants at follow-
up, nonparticipants were similar in age,
sex distribution, estimated IQ, and base-
line brain volumes. The results of the
TICS-malsoshownoselectionbiasdueto
drop out of participants with severely im-
paired cognitive functioning. However,
the relatively healthy patient population
and the risk factor proﬁle of the control
participants could have underestimated
the effects of type 2 diabetes. Finally, the
analysesofthedeterminantswereaffected
by the modest sample size and difﬁculties
inherent to the assessment of these deter-
minants. Diabetes duration, for example,
cannot be ﬁrmly established because dia-
betesdevelopsinsidiouslyandtendstobe
undiagnosed during the ﬁrst years after
onset. In addition, the actual levels of risk
factors such as A1C and blood pressure,
change over time and under the inﬂuence
of treatment.
In conclusion, the greater increase in
lateral ventricular volume over time in pa-
tients with type 2 diabetes as compared
with control participants shows that type 2
diabetesisassociatedwithaslowincreaseof
cerebral atrophy over the course of years.
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